APLS250117P15000
- 0.05
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $32
Oppenheimer Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $42
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $32 to $60
Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Apellis Pharmaceuticals Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Apellis Pharmaceuticals Analyst Ratings
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to a Hold
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating for Apellis Pharmaceuticals: Promising Growth Potential of Syfovre in Geographic Atrophy Market
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Initiated at Equal-Weight by Morgan Stanley
Apellis Pharmaceuticals Analyst Ratings